Paul D. Savage, MD

About Me

Education: BS, Tufts University, 1977; MD, Tufts University School of Medicine, 1981
Internship: Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, 1982
Residency: Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, 1984
Fellowship: University Minnesota Affiliated Hospitals, 1989
Board Certifications: American Board of Internal Medicine, Internal Medicine; American Board of Internal Medicine, Medical Oncology
Memberships: American Association for Cancer Research; American College of Physicians; Connective Tissue Oncology Society; American Society of Clinical Oncology; American Society of Hematology
Positions: Associate Professor, Hematology and Oncology
Departments and Affiliations: Hematology and Oncology

Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma. Savage PD, Lovato J, Brosnihan KB, Miller AA, Petty WJ. Sarcoma. 2016; 2016:4592768.
Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1a in vascular sarcomas. Petty WJ, Aklilu M, Varela VA, Lovato J, Savage PD, Miller AA. BMC Cancer. 2012 Sep; 12:404.
Phase I study of lenalidomide in solid tumors. Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. J Thorac Oncol. 2007 May; 2(5):445-9.
Inflammatory myofibroblastic tumor with bone marrow involvement. A case report and review of the literature. Hagenstad CT, Kilpatrick SE, Pettenati MJ, Savage PD. Arch. Pathol. Lab. Med. 2003 Jul; 127(7):865-7.
Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). Chen MY, Bechtold RE, Savage PD. AJR Am J Roentgenol. 2002 Oct; 179(4):1059-62.